<!– Name:DistributionId Value:8831877 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:19cd81b4-73a6-41ad-b0c8-6e6bedb3ab35 –>
New York, USA, May 09, 2023 (GLOBE NEWSWIRE) — Sinusitis Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market – Optinose, GeneOne Life Science, Lyra, Sanofi, Regeneron, Genentech, AstraZeneca, Sanofi, Bayer, Pfizer
The sinusitis market is anticipated to surge due to the factors such as the launch of novel drugs, increasing healthcare spending and improved diagnosis during the forecasted period (2023–2032) in the 7MM.
DelveInsight’s Sinusitis Market Insights report includes a comprehensive understanding of current treatment practices, sinusitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Sinusitis Market Report
- As per DelveInsight analysis, the sinusitis market is expected to grow positively owing to several underline factors during the study period (2019–2032).
- DelveInsight’s analysis shows that sinusitis cases show an increasing trend in the forecasted period in the United States.
- Globally, leading sinusitis companies such as Optinose US Inc, GeneOne Life Science, Lyra Therapeutics, Sanofi, Regeneron Pharmaceuticals, Genentech, AstraZeneca, Sanofi, Bayer, Pfizer, TRELLIS BIOSCIENCE, Sanotize Research and Development, OptiNose, Biohaven Pharmaceuticals, Keymed Biosciences Co.Ltd, Suzhou Connect Biopharmaceuticals, Ltd., BEAM Alliance, Insmed Incorporated, Lanier Biotherapeutics, GlycoMira, IVIEW Therapeutics Inc., Nota Laboratories LLC, Quorum Innovations, and others are developing novel sinusitis drugs that can be available in the sinusitis market in the coming years.
- Some of the key therapies for sinusitis treatment include OPN-375, Quinine topical nasal spray, Mometasone eluting resorbable scaffold, Dupilumab, Omalizumab, Benralizumab, Telithromycin, Moxifloxacin, PF-06817024, and others.
- Several sinusitis therapies are in various stages of development, and their anticipated launch will drive the sinusitis market forward.
Discover which therapies are expected to grab the major sinusitis market share @ Sinusitis Market Report
Sinusitis is one of the most common primary care diagnoses. It causes significant morbidity, often necessitating time away from work, and is one of the most common reasons why a general practitioner will prescribe antibiotics. Sinusitis is defined as inflammation of the mucosal lining of the paranasal sinuses. However, rhinosinusitis is a more correct word because sinusitis typically accompanies inflammation of the neighboring nasal mucosa. Rhinosinusitis is frequently categorized depending on the length of sinusitis symptoms and inflammation. Acute rhinosinusitis (ARS) is described as sinusitis symptoms lasting over 12 weeks. Chronic rhinosinusitis (CRS) is sinusitis symptoms lasting over 12 weeks. The majority of acute rhinosinusitis is viral in nature and improves on its own. It is critical to differentiate between viral and bacterial rhinosinusitis to avoid providing ineffective antibiotics against viral infections.
Sinusitis Epidemiology Segmentation
The sinusitis epidemiology section provides insights into the historical and current sinusitis patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The sinusitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Sinusitis Prevalent Cases
- Sinusitis Gender-specific Prevalent Cases
- Sinusitis Type-specific Cases
Download the report to understand which factors are driving sinusitis epidemiology trends @ Sinusitis Epidemiological Insights
Sinusitis Treatment Market
Antibiotics, such as amoxicillin, have been suggested as first-line treatment for uncomplicated acute sinusitis for two weeks. The chosen antibiotic must be effective against S. pneumoniae, H. influenza, and M. catarrhalis. Because S. pneumoniae causes rare intracranial and ocular complications of acute bacterial sinusitis, comprehensive coverage for this pathogen is essential. Amoxicillin-clavulanate (Augmentin) is also an effective first-line treatment for acute sinusitis. The inclusion of clavulanate, a beta-lactamase inhibitor, improves H. influenzae and M. catarrhalis coverage. Because of S. pneumoniae resistance, greater amoxicillin dosages (90 mg/kg/day up to 2 g/day) should be investigated.
Cephalosporins such as cefpodoxime proxetil (Vantin) and cefuroxime (Ceftin) are further alternatives for sinusitis treatment. Trimethoprim-sulfamethoxazole (Bactrim), clarithromycin (Biaxin), and azithromycin (Zithromax) may be recommended in individuals allergic to beta-lactams, although they may not provide appropriate coverage for H. influenzae or resistant S. pneumoniae. Penicillin, erythromycin (Suprax), and first-generation cephalosporins such as cephalexin (Keflex, Keftab) are not advised for treating acute sinusitis due to poor antibiotic coverage of the main pathogens.
Mucolytic drugs (guaifenesin) can assist in reducing mucus viscosity for easier clearance and are frequently used in conjunction with decongestants. Some mucolytics are now available over the counter. Saline spray or irrigation can aid in the removal of secretions. Topical corticosteroids are not recommended for acute sinusitis but may benefit chronic sinusitis, nasal polyps, and allergic and nonallergic rhinitis. Antihistamines are not recommended for sinusitis but may be beneficial for underlying allergic rhinitis.
To know more about sinusitis treatment, visit @ Sinusitis Treatment Drugs
Key Sinusitis Therapies and Companies
- OPN-375: Optinose US Inc
- Quinine topical nasal spray: GeneOne Life Science
- Mometasone eluting resorbable scaffold: Lyra Therapeutics
- Dupilumab: Sanofi/Regeneron Pharmaceuticals
- Omalizumab: Genentech
- Benralizumab: AstraZeneca
- Telithromycin: Sanofi
- Moxifloxacin: Bayer
- PF-06817024: Pfizer
Learn more about the FDA-approved drugs for sinusitis @ Drugs for Sinusitis Treatment
The sinusitis market is expected to change in the coming years. Sinusitis is a common cancer treatment modality. As a result, a large population suffers from sinusitis, creating a massive sinusitis market for any new entrant. Moreover, advancements in radiation delivery technology, such as intensity-modulated radiation treatment, can assist in reducing radiation-induced skin toxicity in specific tumour types, such as breast cancer, will also propel the sinusitis market growth. For those at increased risk of sinusitis, prophylactic administration of a topical steroid is preferred, and topical steroids are often used to treat acute instances. Furthermore, there is some interest in using topical antioxidants or oral enzymes to prevent sinusitis, but no apparent effect has been demonstrated yet.
Furthermore, there is a significant deal of interest in better understanding the processes of dermal injury to mitigate the dermatologic consequences of radiation therapy, but prospective data to guide management are currently scarce. Additionally, the sinusitis pipeline is highly robust; many possible therapies are being studied for sinusitis treatment, and it is safe to assume that the therapeutic space will substantially impact the sinusitis market throughout the forecast period.
However, certain factors may affect the growth of the sinusitis market. Despite developments in radiation delivery technology and rising attention to minimising skin responses, sinusitis management has no gold standard. There are few prospective randomised studies on the use of pharmacologic or supportive care treatments, both topical and non-topical, to prevent and cure sinusitis. Several off-label therapy options are now available on the sinusitis market, each with a sizable sinusitis market share and posing a significant challenge to any new entry in the sinusitis market.
Moreover, the sinusitis market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the sinusitis market growth. Furthermore, sinusitis treatment options in cancer have been steadily increasing. This increase in alternative medicines can potentially reduce sinusitis prevalence and hence cause a dip in the growth of the sinusitis market.
|Coverage||7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]|
|Key Sinusitis Companies||Optinose US Inc, GeneOne Life Science, Lyra Therapeutics, Sanofi, Regeneron Pharmaceuticals, Genentech, AstraZeneca, Sanofi, Bayer, Pfizer, TRELLIS BIOSCIENCE, Sanotize Research and Development, OptiNose, Biohaven Pharmaceuticals, Keymed Biosciences Co.Ltd, Suzhou Connect Biopharmaceuticals, Ltd., BEAM Alliance, Insmed Incorporated, Lanier Biotherapeutics, GlycoMira, IVIEW Therapeutics Inc., Nota Laboratories LLC, Quorum Innovations, and others|
|Key Sinusitis Therapies||OPN-375, Quinine topical nasal spray, Mometasone eluting resorbable scaffold, Dupilumab, Omalizumab, Benralizumab, Telithromycin, Moxifloxacin, PF-06817024, and others|
Scope of the Sinusitis Market Report
- Therapeutic Assessment: Sinusitis current marketed and emerging therapies
- Sinusitis Market Dynamics: Attribute Analysis of Emerging Sinusitis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Sinusitis Market Access and Reimbursement
Discover more about sinusitis drugs in development @ Sinusitis Clinical Trials
Table of Contents
|1.||Sinusitis Market Key Insights|
|2.||Sinusitis Market Report Introduction|
|3.||Sinusitis Market Overview at a Glance|
|4.||Sinusitis Market Executive Summary|
|5.||Disease Background and Overview|
|6.||Sinusitis Treatment and Management|
|7.||Sinusitis Epidemiology and Patient Population|
|9.||Sinusitis Marketed Drugs|
|10.||Sinusitis Emerging Drugs|
|11.||Seven Major Sinusitis Market Analysis|
|12.||Sinusitis Market Outlook|
|13.||Potential of Current and Emerging Therapies|
Sinusitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key sinusitis companies, including GeneOne Life Science, Lyra Therapeutics, TRELLIS BIOSCIENCE, Sanotize Research and Development, Sanofi, OptiNose, Biohaven Pharmaceuticals, Keymed Biosciences Co.Ltd, Suzhou Connect Biopharmaceuticals, Ltd., Genentech, Inc., Pfizer, among others.
Sinusitis Epidemiology Forecast
Sinusitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted sinusitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Rhinosinusitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key rhinosinusitis companies, including Kyowa Kirin Co., Ltd., Keymed Biosciences Co.Ltd, Pfizer, GlycoMira Therapeutics, among others.
Rhinosinusitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key rhinosinusitis companies, including Kyowa Kirin Co., Ltd., Keymed Biosciences Co.Ltd, Pfizer, GlycoMira Therapeutics, among others.
Chronic Rhinosinusitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key chronic rhinosinusitis companies, including Connect Biopharma, Lyra Therapeutics, Sanotize Research and Development corp., Regeneron Pharmaceuticals, AstraZeneca, among others.
Chronic Rhinosinusitis Pipeline
Chronic Rhinosinusitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic rhinosinusitis companies, including Connect Biopharma, Lyra Therapeutics, Sanotize Research and Development corp., Regeneron Pharmaceuticals, AstraZeneca, among others.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Sinusitis Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter